

**State of the Art of  
EGFR targeting therapies in mCRC  
"Personalized Treatment  
for mCRC"**

**3<sup>rd</sup> February 2012**

*Venue:*

Hyatt Regency Hotel  
23 Belwederska Avenue  
Warsaw, Poland 00-761  
Tel: +48 22 558 1234 · Fax: +48 22 558 1235  
Email: [warsaw.regency@hyatt.com](mailto:warsaw.regency@hyatt.com)

*Chairs:*

Dr. Lucjan Wyrwicz, Warsaw  
Prof. Christoph Zielinski, Vienna

# Program

CECOG has now finished two studies (the CORE -1 and the CORE -2 Study) which have applied EGFR Inhibitors in metastatic Colorectal Cancer. CORE 1 compared FOLFOX and FOLFIRI both in combination with Cetuximab, CORE 2 investigated the ability to administer Cetuximab in every two weeks.

Whereas the first trial was published in the World Journal of Gastroenterology, the second is still being evaluated regarding the results, but has provided some very interesting preliminary data. In order to further expand on these activities, CECOG is planning to hold educational meetings on the issue within our area.

## *Objectives:*

At the end of the lectures, participants will be able to understand the principles, indications, techniques and limitations of anti-EGFR antibody treatment in metastatic colorectal cancer, will understand efficacy of EGFR antibody therapy in various lines of treatment. They will participate in case discussions and will learn to control therapy-associated side effects.

## Friday **3<sup>rd</sup> November 2011**

13:00	Lunch	
14:00	Welcome to the CECOG meeting	<i>Christoph Zielinski (AT)</i>
14:05	Introduction and meeting objectives	<i>Lucjan Wyrwicz (PL)</i>
14:10	Personalized treatment approach	<i>Krzysztof Krzemieniecki (PL)</i>
14:30	Targeted therapies in the treatment of mCRC	<i>Fortunato Ciardiello (IT)</i>
14:50	How to optimize the therapeutic approach with biologicals in 1st line mCRC	<i>Lucjan Wyrwicz (PL)</i>
15:10	Discussion session with Q &A	<i>Chair</i>
15:20	Coffee Break	
15:35	The importance of multidisciplinary team approach	<i>Klaus Kaczirek (AT)</i>
15:55	Case study	<i>Wojciech Polkowski (PL)</i>
16:15	Tumor shrinkage impact on long term survival in mCRC	<i>Piotr Wysocki (PL)</i>
16:35	Discussion session with Q&A	<i>Chair</i>
16:45	Coffee Break	
17:00	CECOG experience - EGFR in mCRC cancer: The CORE 1 and CORE 2 trial update	<i>Christoph Zielinski (AT)</i>
17:20	Prophylactic dermatological treatment of skin toxicity	<i>Janja Ocvirk (SL)</i>
17:40	Summary: optimal treatment strategies in mCRC	<i>Fortunato Ciardiello (IT)</i>
18:00	Meeting close	<i>C. Zielinski (AT)/L. Wyrwicz (PL)</i>